---
title: 'Clinical Outcomes After Idecabtagene Vicleucel in Older Multiple Myeloma Patients:
  A Multicenter Real-world Experience'
date: '2024-07-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39042903/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240724182938&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: The safety and efficacy of CAR T-cell therapy is not well described in
  older patients, a population that has higher frailty and co-morbidities. In this
  multicenter retrospective study, we evaluated clinical outcomes along with frailty
  and geriatric characteristics such as comorbidities, polypharmacy, falls, neuropathy,
  organ dysfunction, and performance status in younger (<65 years) versus older (≥65
  years) patients who received commercial idecabtagene vicleucel (ide-cel). A total
  of ...
disable_comments: true
---
The safety and efficacy of CAR T-cell therapy is not well described in older patients, a population that has higher frailty and co-morbidities. In this multicenter retrospective study, we evaluated clinical outcomes along with frailty and geriatric characteristics such as comorbidities, polypharmacy, falls, neuropathy, organ dysfunction, and performance status in younger (<65 years) versus older (≥65 years) patients who received commercial idecabtagene vicleucel (ide-cel). A total of ...